Abstract Among the eight naturally occurring vitamin E analogs, c-tocotrienol (GT3) is a particularly potent radioprophylactic agent in vivo. Moreover, GT3 protects endothelial cells from radiation injury not only by virtue of its antioxidant properties but also by inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase and by improving the availability of the nitric oxide synthase cofactor tetrahydrobiopterin. Nevertheless, the precise mechanisms underlying the superior radioprotective properties of GT3 compared with other tocols are not known. This study, therefore, examined the differences in gene expression profiles between GT3 and its tocopherol counterpart, c-tocopherol, as well as between GT3 and a-tocopherol in human endothelial cells. Cells were treated with vehicle or the appropriate tocol for 24 h, after which total RNA was isolated and genome-wide gene expression profiles were obtained using the Illumina platform. GT3 was far more potent in inducing gene-expression changes than a-tocopherol or c-tocopherol. In particular, GT3 induced multiple changes in pathways known to be of importance in the cellular response to radiation exposure. Affected GO functional clusters included response to oxidative stress, response to DNA damage stimuli, cell cycle phase, regulation of cell death, regulation of cell proliferation, hematopoiesis, and blood vessel development. These results form the basis for further studies to determine the exact importance of differentially affected GO functional clusters in endothelial radioprotection by GT3.
Introduction
Exposure to high doses of ionizing radiation can cause severe, sometimes even life threatening injury to normal tissues. Radiation-induced tissue injury may occur both in clinical and nonclinical settings. In patients treated with radiotherapy, normal tissue radiation toxicity is the most important cause of treatment-related side effects, and thus limits the uncomplicated cancer cure rate. Nonclinical exposure with high radiation doses may occur in emergency situations, such as radiological/nuclear accidents or terrorist attacks. Under such circumstances, radiation exposure may cause substantial mortality.
Because of the potential impact of radiation injury and the limited availability of effective radioprotectants, there is an ongoing quest to develop novel pharmacological agents that can prevent or mitigate normal tissue radiation injury. Because of relatively potent antioxidant properties and lack of performance-degrading side effects, vitamin E analogs, collectively referred to as tocols, are considered to be attractive candidate agents for radioprotection. In recent years, various tocols have been tested for their radioprotective potential (Berbee et al. 2009; Kumar et al. 2002; Singh et al. 2006) . Important structural and functional differences exist between the different tocols. Tocopherols and tocotrienols differ in the side chain that is attached to the chroman ring. Whereas tocopherols have a saturated phytyl side chain, tocotrienols have an unsaturated isoprenoid chain. The four isoforms, a-, b-, d-and c-, differ in the number and position of methyl groups on the chroman ring.
Most studies on the effects of vitamin E on radiation injury were conducted with a-tocopherol, the most commonly used vitamin E supplement and the vitamin E isoform that is most abundant in human and animal tissues (Bichay and Roy 1986; Felemovicius et al. 1995; Odagiri et al. 1992; Ramos et al. 2006; Singh et al. 2006; Srinivasan and Weiss 1992) . However, recent studies have shown that other members of the tocol family, c-tocotrienol (GT3) in particular, are far more effective in reducing acute radiation toxicity and protecting from lethality. In a direct side-by-side comparison, Kumar et al. demonstrated that GT3 is superior to a-tocopherol in reducing lethality after total body irradiation (TBI) in mice (Kumar et al. 2008) . Subsequent studies have shown that the radioprotective properties of GT3 not only depend on its antioxidant action but also on the modulation of endothelial cell function (Berbee et al. 2009 ). Endothelial dysfunction is a prominent feature of early as well as late radiation injury and has been shown to play an important role in the pathogenesis of radiation toxicity in various organ systems (Baker and Krochak 1989; Hopewell et al. 1993; Jaenke et al. 1993; Lyubimova and Hopewell 2004; Maj et al. 2003; Paris et al. 2001; Rezvani et al. 1995; Wang et al. 2002 Wang et al. , 2007 .
The exact mechanisms underlying the superior radioprotective effects of GT3 and, in particular, how GT3 reduces radiation-induced endothelial dysfunction has not been elucidated. GT3, in contrast to a-tocopherol, is a potent inhibitor of endothelial 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase (Parker et al. 1993; Song and DeBose-Boyd 2006) . Moreover, after radiation exposure of mice in vivo, GT3 reduces radiation-induced vascular oxidative stress in an HMG-CoA reductase dependent manner (Berbee et al. 2009 ). GT3 may also exert its beneficial inhibitory effects on postirradiation free-radical production by improving the availability of the endothelial nitric oxide synthase (eNOS) cofactor BH4 through downregulation of GTP-cyclohydrolase 1 regulatory protein (GFRP), thereby enhancing the production of NO and reducing the production of ONOO-by eNOS (Berbee et al. 2011) . Finally, GT3 has been shown to improve the postirradiation recovery of plasma markers of endothelial function, an effect that is not dependent of HMG-CoA reductase inhibition (Berbee et al. 2009 ).
In order to improve our understanding of the mechanisms responsible for the differences in radioprotective potential of the various tocols, we performed a series of gene-expression experiments to compare GT3, c-tocopherol, and a-tocopherol. By identifying the genomic functional pathways that are differentially regulated by GT3 compared to the other two tocols, several candidate pathways and genes were identified. These findings offer opportunities for future mechanistic studies to determine the exact mechanism by which GT3 confers superior radioprotection in vivo and for development of novel analogs to further enhance these properties.
Methods
Cell culture and reagents Unless otherwise specified, chemicals were obtained from Sigma-Aldrich (St. Louis, MO). a-tocopherol, c-tocopherol, and GT3 were acquired from Yasoo Health Inc. (Johnson City, TN) and were dissolved in ethanol to obtain stock solutions of 50 mM. Tocol stock solutions were stored in liquid nitrogen.
Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Walkersville, MD), and cell cultures were performed as described previously (Boerma et al. 2006) . HUVECs were cultured in EGM-2 medium with growth supplements (Lonza). Passage 4-6 cells were used in the experiments. After 2 days (confluence 90%), the cells were incubated for 24 h in 3 ml culture media containing vehicle (ethanol), 5 lM a-tocopherol, 5 lM c-tocopherol, or 5 lM GT3. The cells were harvested after 24 h of incubation. Total RNA was isolated using Ultraspec. The experiments were performed in triplicate.
Arrays
Microarrays were used to determine tocol-induced changes in gene expression profiles in the HUVEC cells. Both the generation of aRNA and microarray hybridization were performed by the Microarray Core Laboratory of the University of Texas Health Science Center (Houston, TX). All RNA samples were tested for integrity and minimal degradation using an Agilent Bioanalyzer 2100. Two hundred nanogram of total RNA was reverse transcribed and amplified overnight with T7 RNA polymerase and labeled with biotin following the manufacturer's protocol, in which 1.5 mg of biotin labeled aRNA was hybridized to microarrays at 58°C overnight. Illumina Genome-Wide Expression BeadChips (Human Ref-6 v 2.0, Illumina, San Diego, CA), representing *43,000 human transcripts (Kuhn et al. 2004) , were used. Arrays were incubated with Cy3 streptavidin and washed according to the manufacturer's protocol. Initial analysis of the microarray data was done using Illumina's Beadstudio V1. After background subtraction, arrays were normalized to each other by rankinvariant normalization. Changes in gene expression were tested using a modified t test that employs estimates of variation that include sequence-specific biological variation (r bio ), nonspecific biological variation (r neg ), and technical error (r tech ), according to the Illumina User Guide (2005), rev B. Genes were considered differentially regulated at P \ 0.001.
Genes that were up-or downregulated by a-tocopherol, c-tocopherol, or GT3 were classified according to Gene Ontology (GO) biological processes and KEGG pathways using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 (Ashburner et al. 2000; Huang et al. 2009 ). GO biological processes with a P \ 0.05 were considered to be differentially regulated.
Results
No signs of cell toxicity were observed after incubation with 5 lM of a-tocopherol, c-tocopherol, or GT3 for 24 h. There were major differences in the quantity of genes upor downregulated by the different tocols. GT3 was by far the most potent, with a differential expression of 898 genes (Fig. 1) . In comparison, at the 5 lM concentration level, a-tocopherol and c-tocopherol only changed the expression of 39 and 172 genes, respectively. There was limited overlap between the genes differentially expressed after treatment with the different tocols. There were only 2 genes upregulated by all 3 tocols: PMPCA and LOC642755.
In order to obtain information about the functional effects of up-and downregulated genes, the differentially regulated genes were classified according to GO biological processes. Both c-tocopherol and GT3 affected genes involved in the regulation of cell death (Table 1) . GT3 modified a total of 233 GO biological processes (Fig. 2) . The affected GO functional clusters included several processes known to be of importance in the cellular response to ionizing radiation: response to oxidative stress (GO: 0006979) (see supplemental data for gene list), response to DNA damage stimuli (GO:0006974) (see supplemental data for gene list), cell cycle phase (GO:0022403), regulation of cell death (GO: 0010941), regulation of cell proliferation (GO:0042127), regulation of inflammatory response (GO:0050727), hematopoiesis (GO:0030097), and blood vessel development (GO:0001560) ( Table 2 ; Fig. 3 ).
Gene expression in GT3-treated cells was also directly compared with gene expression in cells treated with a-tocopherol and c-tocopherol. Relative to a-tocopherol and c-tocopherol, GT3 up-or downregulated 102 and 84 genes, respectively. These genes corresponded to 90 and 42 GO biological pathways, respectively (Fig. 4) . Compared to a-tocopherol, GT3 regulated various processes involved in the regulation of cell death. Compared to both a-tocopherol and c-tocopherol, GT3 regulated several processes that are of importance in the response to and the recovery from radiation exposure, like regulation of cell proliferation (GO:0042127), regulation of inflammatory response (GO:0050727), and leukocyte migration (GO:0050900) (see supplemental data for a complete list of the differentially regulated pathways).
Discussion
The potent radioprotective properties of the vitamin E analog GT3 depend, at least partially, on protection of endothelial cell function. Recent gene expression studies using tumor cell lines and immune cells have shown that different tocols may induce distinct differential changes in these cell lines (Campbell et al. 2009; Han et al. 2010 ; Fig. 1 Venn diagram of up-and downregulated genes in endothelial cells 24 h after treatment with a-tocopherol (aTOC) (5 lM), c-tocopherol (gTOC) (5 lM), or c-tocotrienol (GT3) (5 lM). GT3 affected a total number of 898 genes, whereas aTOC and gTOC only affected 39 and 172 genes, respectively. There was limited overlap in up-and downregulated genes between the different tocols. Only 2 genes were affected by all 3 tocols. Genes were considered differentially regulated at P \ 0.001 Genes Nutr (2012) 7:75-81 77
Wu and Ng 2010), suggesting that the same may apply to endothelial cells. With this study, we aimed to explore whether there are marked differential changes in endothelial gene expression after treatment with GT3, c-tocopherol, and a-tocopherol and whether these tocols differentially regulate functional gene clusters known to be important in the cellular response to radiation. The present study thus sheds light on the mechanism underlying the superior radioprotective properties of GT3 compared to other tocols. The specific comparison of GT3 with a-tocopherol and c-tocopherol was performed because a-tocopherol is the most abundant tocol and because c-tocopherol and GT3 share structural similarities with regard to the chroman ring. However, c-tocopherol and GT3 have different side chains: tocotrienols contain an isoprenoid side chain with three double bonds, whereas tocopherols have a (saturated) phytyl side chain. These structural variations are believed Fig. 2 Venn diagram of differentially regulated Gene Ontology (GO) biological functional gene clusters in endothelial cells 24 h after treatment with a-tocopherol (aTOC) (5 lM), c-tocopherol (gTOC) (5 lM), or c-tocotrienol (GT3) (5 lM). GT3 affected a total number of 233 GO functional clusters, whereas aTOC and gTOC only affected 2 and 25 clusters, respectively. Ten GO functional clusters were identified that were both affected by GT3 and gTOC. GO functional cluster was considered differentially regulated at P \ 0.05 Table 2 Selection of Gene Ontology (GO) biological functional gene clusters regulated by c-tocotrienol (GT3) (5 lM) and expected to be of importance in the response to and recovery from radiation exposure to result in functional differences between the different tocols that are thought to be due to differences in distribution in lipid bilayers, more efficient interaction with the chroman ring in tocotrienols with the lipid bilayer, and differences in cellular uptake (Aggarwal et al. 2010) . Remarkably, as a result of the latter effect, GT3 GO:0042127~regulation of cell proliferation GO:0050727~regulation of inflammatory response GO:0050900~leukocyte migration GO:0042981~regulation of apoptosis GO:0043067~regulation of programmed cell death GO:0010941~regulation of cell death Fig. 4 Venn diagram of differentially regulated Gene Ontology (GO) biological functional gene clusters of genes up-or downregulated by c-tocotrienol (GT3) (5 lM) compared with a-tocopherol (aTOC) (5 lM) and c-tocopherol (gTOC) (5 lM). GT3 regulated several Gene Ontology (GO) biological functional gene clusters that are expected to be of importance in the response to and recovery from radiation exposure. GO functional cluster was considered differentially regulated at P \ 0.05
Genes Nutr (2012) 7:75-81 79 accumulates in endothelial cells to levels that are 30-50 fold greater compared with alpha-tocopherol (Naito et al. 2005; Noguchi et al. 2003) .
Comparative gene expression profiling in endothelial cells treated with different tocols revealed major differences in gene expression between the different treatment groups. Notably, GT3 was far more potent in inducing gene-expression changes than a-tocopherol or c-tocopherol. Relative to vehicle-treated control cells, both GT3 and c-tocopherol-induced gene clusters associated with the regulation of cell death and apoptosis, processes that clearly play an important role in the development of acute radiation toxicity. Moreover, compared to vehicle, GT3 induced multiple changes in several other pathways known to be important in the cellular response to radiation. Affected GO functional clusters included response to oxidative stress, response to DNA damage stimuli, cell cycle phase, regulation of cell proliferation, regulation of inflammatory response, blood vessel development, and hematopoiesis. Modification of these processes, as seen after treatment with GT3, can be expected to alter cellular radiation sensitivity and/or the ability to recover from the effects of radiation exposure. Further research is needed to determine the exact importance of the different processes in the mechanism underlying the radioprotective properties of GT3 and to identify the key regulatory genes.
GT3 is significantly more effective as a radioprotectant than most other tocols. By comparing gene expression in GT3-treated cells directly with gene expression in cells treated with a-tocopherol and c-tocotrienol, as well as by analyzing differentially regulated functional gene clusters, we aimed to identify pathways that may be responsible for the difference in radioprotective effects of these tocols. With respect to processes that are known to regulate important cellular responses to radiation, GT3 distinguished itself from both a-tocopherol and c-tocopherol by regulating gene clusters involved in cell proliferation and the inflammatory response. Moreover, compared to a-tocopherol, GT3 regulated several gene groups involved in the regulation of cell death.
Tocotrienols exert their effect on several different molecular levels. Hence, they modulate their targets not only at the transcriptional level but also at the translational or post-translational levels or by direct interaction with the substrate (Aggarwal et al. 2010) . Therefore, the radioprotective effects of GT3 can also be a result of modifications at various levels. For example, this may explain why, in the current study, we did not observe changes in the gene expression levels of HMG-CoA reductase, even though the inhibition of HMG-CoA reductase is known to play an important role in the mechanism underlying GT3-induced regulation of endothelial cell function and radioprotection. In fact, GT3 regulates the activity of HMG-CoA reductase by enhancing proteasomal degradation of the enzyme (Parker et al. 1993; Song and DeBose-Boyd 2006) . GT3, like d-tocotrienol, stimulates ubiquitination of HMG-CoA reductase by Insig proteins, thus targeting the enzyme for degradation by the 26S proteasome. Therefore, a direct change in gene expression levels of the enzyme would not be expected.
In a previous study, we provided evidence to support that GT3 exerts some of its beneficial effects on postirradiation free-radical production by improving the availability of the endothelial nitric oxide synthase (eNOS) cofactor BH4 through downregulation of GTP-cyclohydrolase 1 regulatory protein (GFRP) (Berbee et al. 2011) . We showed that GT3 induced a small, but highly significant, decrease in GFRP transcription, gene expression, and protein level in vitro and abrogated the early decrease in BH4 levels observed in vivo. The observation from the current experiment that GFRP was not among the genes downregulated by GT3 seemingly contradicts these data. However, this might be caused by a difference in sensitivity of the methods used in our previous experiments and the microarray analysis used in the current study or because of a difference in GT3 concentration between the two studies.
A recent study by Li et al. showed that d-tocotrienol protects mouse and human hematopoietic progenitors from c-irradiation through Erk activation-associated mTOR survival pathways (Li et al. 2010) . In contrast, in our current experiment, no evidence was found suggesting that GT3 conveys endothelial radioprotection through Erk/ mTOR signaling. This difference may be either a result of differences between c-tocotrienol and d-tocotrienol or, alternatively, depend on the studied cell type.
Taken together, our data demonstrate that GT3 is substantially more effective in inducing gene-expression changes in endothelial cells than a-tocopherol, the standard vitamin E compound, or c-tocopherol, its saturated structural analog. Moreover, GT3 induced multiple changes in functional genetic pathways known to be of critical importance in the regulation of cellular responses to radiation exposure, such as response to oxidative stress, response to DNA damage stimuli, cell cycle phase, regulation of cell death, regulation of cell proliferation, hematopoiesis, and blood vessel development. These results form the basis for further studies to assess the importance of the different affected GO functional clusters in in vivo GT3-induced radioprotection.
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